Reports Q3 revenue $2.24B, consensus $2.15B. “We are pleased with our solid third-quarter performance, as each of our business segments posted year-over-year revenue growth on both a reported and organic basis. We remain focused on advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive global growth,” said Thomas J. Appio, Chief Executive Officer, Bausch Health.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BHC:
- Bausch says district court misses Norwich suit against FDA
- Denial of Norwich’s injunction motion ‘slightly positive’ for Bausch, says RBC
- Bausch Health call volume above normal and directionally bullish
- Bausch Health unveils ‘Looking Forward’ television campaign
- Bausch Health price target lowered to $8 from $9 at RBC Capital